Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31345511 | 0.78 | PIK3CA (0.37) | ALDH1A1MAPTMAPK1POLBCYP3A4 | |
| SCHEMBL1674658 | 0.78 | PIK3CA (0.37) | ALDH1A1MAPTMAPK1POLBCYP3A4 | |
| SCHEMBL19171973 | 0.74 | IRAK4 (0.36) | GRM5 | |
| SCHEMBL19171944 | 0.73 | MBOAT4 (0.42) | POLB | |
| SCHEMBL5697548 | 0.73 | ALDH1A1 (0.42) | KMT2AMEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL1559757 | 0.72 | P2RX7 (0.36) | MAPK1CYP3A4TSHR | |
| SCHEMBL29939860 | 0.72 | P2RX7 (0.36) | MAPK1CYP3A4TSHR | |
| SCHEMBL18072298 | 0.71 | NUDT1 (0.66) | KDM4ENUDT1 | |
| SCHEMBL3378270 | 0.71 | TSHR (0.38) | BRAFKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL14464127 | 0.70 | NOS3 (0.38) | KMT2AALDH1A1MAPTMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436000-B2 | Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2307024-B1 | SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20110124662-A1 | Substituted Carbamate Derivatives as Modulators of Corticotropin-Releasing Factor Receptor Activity | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-26 | — | — | US | disclosed |
| EP-2307024-A1 | SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010014687-A1 | SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124662-A1 | Substituted Carbamate Derivatives as Modulators of Corticotropin-Releasing Factor Receptor Activity | CRH, CRHR1, CRHR2 | BRAF 4362/4885KMT2A 3267/4885MEN1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.